In the face of mounting criticism over insulin prices, Novo Nordisk (NVO) is mimicking its rivals by launching two programs that are designed to mitigate rising costs for patients.
The two-pronged effort involves a $99 cash card that can be used by anyone — regardless of whether they have insurance coverage — for a month’s supply and the introduction of authorized generic versions of two different insulin products at half the list price. These will be identical to the Novolog and Novolog Mix brand-name treatments and will be made at the same facility, but will carry modified labeling.
About the Author Reprints
